Novartis Oncology Press Releases http://www.novartisoncology.com Higher initial dose of Glivec achieved better early responses than standard dose for patients with chronic myeloid leukemia 2008-06-13T07:30:00 CET /media/press-releases.jsp??id=1227552&year=2008
  • Efficacy and safety profile in large randomized Phase III study consistent with landmark IRIS trial, which established Glivec as standard of care
  • Study did not meet primary endpoint at 1 year, yet shows faster time to molecular responses with 800 vs. 400 mg dose
  • Findings reinforce that monitoring blood levels of Glivec may help optimize treatment benefit for individual patients
  • Novartis committed to improving first-line treatment through additional study follow-up and completing enrollment to Tasigna vs. Glivec trial
    • ]]>         Early data presented at ASCO show potential of RAD001 to enhance efficacy of, and overcome resistance to, breast cancer treatments 2008-06-02T07:15:00 CET /media/press-releases.jsp??id=1224201&year=2008
  • Randomized Phase II data show RAD001 significantly increased efficacy of letrozole in women with newly diagnosed hormone-positive breast cancer
  • Phase I studies suggest RAD001 may help overcome a major pathway of resistance to trastuzumab
  • Novartis to further explore potential of RAD001 in breast cancer by initiating new trial in early 2009
    • ]]>         Major independent trial demonstrates significant anticancer benefit of Zometa® in women with early-stage breast cancer 2008-05-31T16:00:00 CET /media/press-releases.jsp??id=1224091&year=2008
  • Zometa when added to hormone therapy, following surgery, significantly reduced the risk of cancer returning or death by 36% beyond clinical benefits achieved with hormone therapy alone[1]
  • Findings may allow clinicians to improve standard of care for premenopausal women diagnosed with hormone-sensitive, early-stage breast cancer
  • These are the first data from a large clinical program exploring the direct anticancer effect of Zometa in breast, lung and prostate cancer
    • ]]>         RAD001 more than doubles time without tumor growth after failure of standard treatment in patients with advanced kidney cancer 2008-05-19T07:15:00 CET /media/press-releases.jsp??id=1220385&year=2008
  • RECORD-1 trial shows RAD001 reduces risk of disease progression by 70%
  • RAD001 is first and only drug to show significant benefit after failure of approved therapies Sutent® or Nexavar®,** with potential to address unmet medical need
  • Once-daily oral RAD001 directly targets and continuously inhibits mTOR, a protein that controls tumor cell division and blood vessel growth
  • RAD001 is currently being studied in multiple types of cancer including neuroendocrine, breast, gastric, lung, and lymphoma
    • ]]>         Strength and innovation of Novartis Oncology products and pipeline with potential to improve patient treatment demonstrated by more than 170 abstracts at ASCO annual meeting 2008-05-15T22:15:00 CET /media/press-releases.jsp??id=1219879&year=2008
  • Unprecedented amount of research reflects depth and breadth of collaboration with investigators worldwide to develop new treatments for diverse forms of cancer
  • Plenary session to highlight impact of Zometa®, the leading IV bisphosphonate, on relapse rate of patients with early-stage breast cancer
  • Four oral sessions to feature RAD001, first oral once-daily continuous inhibitor of mTOR, including first results of RECORD-1 study in renal cell carcinoma
  • Updated Phase II results with Tasigna® in Philadelphia chromosome-positive chronic myeloid leukemia to be presented
    • ]]>         ASA404, a novel cancer agent, begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death 2008-04-11T07:15:00 CET /media/press-releases.jsp??id=1208459&year=2008
  • With launch of Phase III ATTRACT-1 trial in non-small cell lung cancer, Novartis Oncology assumes responsibility for development of ASA404 from Antisoma
  • Novel mechanism of action of ASA404 disrupts existing blood supply to tumors
  • Tumor-Vascular Disrupting Agent is one of six Novartis Oncology compounds in late-stage development for various solid tumors and blood cancers]]> Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy 2008-03-10T23:00:00 CET /media/press-releases.jsp??id=1199700&year=2008
  • Post-unblinding analysis of MA-17 trial data provides evidence for potential benefit of starting Femara up to seven years after finishing tamoxifen
  • Femara only member of aromatase inhibitor class with data demonstrating this potential benefit, as published in Journal of Clinical Oncology
  • Half of all breast cancer recurrences occur five or more years after diagnosis
  • Separate analysis published in Annals of Oncology affirms significant advantages of Femara when taken after standard tamoxifen therapy
    • ]]>         Everolimus (RAD001) significantly extends progression-free survival in advanced kidney cancer patients after failure of other targeted therapy 2008-02-28T07:00:00 CET /media/press-releases.jsp??id=1196020&year=2008
  • Outstanding interim results cause independent data monitoring committee to immediately share findings; patients on placebo to be offered everolimus
  • Everolimus (RAD001) tablet, taken once daily, demonstrated highly effective anti-tumor activity through continuous targeted inhibition of mTOR
  • Results of RECORD-1 trial address unmet medical need in renal cell cancer with worldwide regulatory filings planned for second half of 2008
  • Complete results to be submitted as late-breaking abstract for presentation at the American Society of Clinical Oncology meeting
    • ]]>         New data show Glivec® halts progression to advanced stages of life-threatening form of leukemia in sixth year of treatment 2007-12-09T22:30:00 CET /media/press-releases.jsp??id=1174545&year=2007 Tasigna® gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies 2007-11-28T07:15:00 CET /media/press-releases.jsp??id=1171279&year=2007